All Publications
3 min read

IRS Finalizes Rules on CRAT Listed Transactions and Insurance Policy Transfers: Disclosure Obligations, Reportable Policy Sales, and M&A Due Diligence Implications | ULF New York

Tax & Estate Planning

IRS Finalizes Rules on CRAT Listed Transactions and Insurance Policy Transfers: Disclosure Obligations, Reportable Policy Sales, and M&A Due Diligence Implications

Treasury and IRS finalized rules identifying certain charitable remainder annuity trust structures as listed transactions, triggering disclosure obligations for participants and material advisors. IRS also finalized rules on transfer-for-value and information-reporting requirements for reportable policy sales, section 1035 exchanges, and life-insurance acquisitions in corporate reorganizations. Tax counsel, estate planners, and M&A advisors should update due diligence checklists and disclosure procedures.

3 min read

Two Separate Final Rules

Treasury and the IRS issued two sets of final rules with significant implications for tax planning, estate planning, and M&A transactions involving life insurance:

  1. Final regulations identifying certain charitable remainder annuity trust (CRAT) structures as listed transactions
  2. Final regulations on transfer-for-value rules and information-reporting requirements for reportable policy sales, section 1035 exchanges, and life-insurance acquisitions in corporate reorganizations

Part 1: CRAT Listed Transaction Rules

A charitable remainder annuity trust (CRAT) is a split-interest trust that pays a fixed annuity to non-charitable beneficiaries for a term of years or for life, with the remainder passing to a charitable organization. CRATs are a legitimate estate and charitable planning tool when properly structured.

The IRS has identified certain CRAT structures as listed transactions — a designation that triggers mandatory disclosure obligations for both participants and material advisors. The targeted structures are those the IRS views as abusive — typically arrangements designed to generate inflated charitable deductions or to extract value from the trust in ways that circumvent the rules governing CRATs.

Disclosure Obligations

  • Participants: Must disclose on Form 8886 (Reportable Transaction Disclosure Statement). Failure to disclose carries penalties up to $10,000 for individuals and $50,000 for entities per year of non-disclosure.
  • Material advisors: Must file Form 8918 (Material Advisor Disclosure Statement) and maintain a list of advisees. Penalties for failure to disclose can reach $200,000 per transaction.

Practical Steps Tax counsel and estate planners should review existing CRAT arrangements against the final regulations’ listed transaction description, assess whether disclosure obligations have been triggered, and update engagement letters and due diligence procedures.

Part 2: Transfer-for-Value and Reportable Policy Sale Rules

Life insurance death benefits are generally excluded from gross income under section 101(a). However, the transfer-for-value rule (section 101(a)(2)) provides that if a life insurance contract is transferred for valuable consideration, the death benefit exclusion is limited — the recipient can only exclude the consideration paid plus premiums subsequently paid.

The Tax Cuts and Jobs Act of 2017 added section 6050Y, creating information-reporting requirements for "reportable policy sales" — acquisitions of life insurance contracts for valuable consideration where the acquirer has no substantial family, business, or financial relationship with the insured.

The final regulations implement these reporting requirements, specifying who must report, what must be reported, when reports must be filed, and the forms to be used (Forms 1099-LS and 1099-SB).

Section 1035 Exchanges The final regulations address when a section 1035 exchange constitutes a reportable policy sale triggering information-reporting obligations.

M&A Due Diligence Implications When acquiring a company that holds life insurance policies — key-man insurance, split-dollar arrangements, or COLI programs — acquirers must:

  • Identify all life insurance policies held by the target
  • Determine whether any prior transfers triggered the transfer-for-value rule
  • Assess the tax treatment of death benefits under the policies
  • Review information-reporting obligations associated with the acquisition
  • Consider whether the acquisition itself constitutes a reportable policy sale

Failure to conduct this analysis can result in unexpected tax liability — loss of the death benefit exclusion — and information-reporting penalties.

Conclusion

The IRS’s finalization of the CRAT listed transaction rules and the reportable policy sale regulations represents a significant tightening of the tax compliance framework for charitable planning and life insurance transactions. Tax counsel, estate planners, and M&A advisors should treat these final rules as a prompt to review existing arrangements and update due diligence and disclosure procedures.

Explore Topics

#IRS#CRAT#Listed Transaction#Charitable Remainder Trust#Life Insurance#Reportable Policy Sale#Transfer for Value#Section 1035#M&A#Estate Planning#Tax Disclosure#Material Advisor

Share this article

X
ULF New York Bülteni

ABD Hukuk Rehberlerini
Doğrudan Alın

E-posta adresiniz yalnızca ULF New York hukuki içerikleri için kullanılır. İstediğiniz zaman aboneliğinizi iptal edebilirsiniz.

Related analysis and guides

Further Reading

Regulatory Developments4 min read

IRS Finalizes CRAT Listed Transaction Rules and Insurance Policy Transfer Requirements

Treasury and IRS finalized rules identifying certain charitable remainder annuity trust structures as listed transactions, triggering disclosure obligations for certain participants and material advisors. IRS also finalized rules on transfer-for-value and information-reporting requirements for reportable policy sales, section 1035 exchanges, and certain life-insurance contract acquisitions in corporate reorganizations.

Read article
M&A Monitoring6 min read

Diodes Incorporated Acquires ElevATE Semiconductor for Up to $300M in Cash and Earn-Out

Diodes Incorporated (Nasdaq: DIOD) has entered into a definitive agreement to acquire ElevATE Semiconductor, Inc. for a base cash consideration of $250 million, plus up to $50 million in earn-out payments tied to 2027–2030 revenue and gross margin targets, for a total potential deal value of approximately $300 million. ElevATE is a fabless designer of low-power, high-density integrated circuits for automated test equipment (ATE) systems. The seller is a continuation fund managed by Presidio Investors. The transaction is expected to close in H2 2026, subject to HSR clearance.

Read article
M&A Monitoring7 min read

SmartStop-Affiliated Storage REITs Merge: SST VI Acquires SSGT III in All-Stock Transaction

Strategic Storage Trust VI (SST VI) has entered into a definitive merger agreement to acquire Strategic Storage Growth Trust III (SSGT III) in an all-stock transaction. Both entities are sponsored and managed by the SmartStop platform. The combined portfolio is expected to have a total asset value of approximately $1.2 billion, comprising 37 directly owned self-storage facilities and approximately 29,415 units across the U.S. and Canada. The transaction is expected to close in Q4 2026, subject to SSGT III stockholder approval and SEC registration.

Read article
M&A Monitoring4 min read

Danaher's Leica Biosystems Acquires StatLab Medical Products: Expanding the Anatomic Pathology Platform

Leica Biosystems, a Danaher Corporation operating company, has signed a definitive agreement to acquire StatLab Medical Products from Linden Capital Partners and Audax Private Equity. The transaction adds pre-analytic and analytic histology consumables and workflow products to Leica's existing portfolio of pathology instruments, digital pathology, and AI-assisted cancer diagnostics. Financial terms were not disclosed. Closing is expected by year-end 2026.

Read article

Published

Wednesday, July 8, 2026

Back to Publications